2023-10-18
同时，通过本次合作，该MNC将迅速推进无血清细胞培养基的新原料发现与验证，及培养基工艺的深度优化，将大幅提高生物制品研发和培养基供应效率，提升无血清细胞培养基的未来发展。
Accepted for Both Oral Presentation and Poster! Two Great Bay Bio Technology Advancements Enabling Antibody R&D for Obesity Targets Selected for Obesity Week® 2026
2026-08-12
AlfaCell Platform Enables Client’s Out-Licensed Pipeline to Successfully Enter Phase II Clinical Trials, Advancing Novel Drugs and Biosimilars in Parallel
2026-08-07
Platform Case | AI Tackles Challenging GPCR Drug Target in 8 Months! AlfaBodY Platform of Great Bay Bio Generates Long-Acting Non-Rebound Weight-Loss Antibody; Research Findings Published
2026-07-17
